Business Wire

FII-INSTITUTE

7.9.2021 23:55:11 CEST | Business Wire | Press release

Share
FII Institute Invests in Interstellar Lab, Accelerating Sustainable Farming on Earth and in Space

Population projections stress the need for sustainable living on our planet and on others. FII Institute announces today an investment in Interstellar Lab, a space technology company designing closed loop biodomes for sustaining life on Earth, the moon, and Mars.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005919/en/

FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. The $500,000 USD equity investment is a part of Interstellar Lab's latest $3M USD Seed Round and builds on FII Institute's commitment to catalyze globally relevant, real-world solutions in Artificial Intelligence and Robotics, Education, Healthcare and Sustainability. Through the investment, the Institute will fund the development of, and leverage, AI simulation-based designs to tackle Earth’s most pressing environmental issues, paving the way to solutions in waste management, zero-impact living and resource-conscious agriculture.

“Climate change is a real emergency for Earth, and we only have a small window to bring about positive change. We are developing a new framework for sustainable living on Earth and a testbed for future space missions,” Barbara Belvisi, Founder and CEO, Interstellar Lab said. “Working with investors like FII Institute advances Interstellar Lab’s mission to support human life sustainably on Earth, the moon and Mars by generating and recycling food, water and air.”

FII Institute CEO Richard Attias said, "Space sector growth is creating new opportunities for advanced research and solutions in sustainability. Inspired by the design challenge of human settlement on Mars, Interstellar Lab has forged an innovative approach to sustaining life in the absence of the abundance taken for granted here on Earth. We are very pleased to support the technologies that will help reduce the burden on our planet and prepare us for the future."

This marks the third FII Institute investment this year following announcements to back Lilium, an electric-powered aircraft reducing the carbon impact of regional travel, and Red Sea Farms, AgTech making it possible to grow food using saltwater. With an inclusive agenda built on three pillars – THINK, XCHANGE, ACT – FII Institute empowers the brightest minds to leverage scientific innovation for positive change, brings leading solutions to reality through investment, and calls for global collaboration in the service of humanity.

About FII Institute (Future Investment Initiative Institute)

FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. Committed to Environmental, Social and Governance (ESG) principles, we foster the brightest minds and transform ideas into real-world solutions.

When decision makers, investors and an engaged generation of youth come together, energized and ready for change, we harness that energy into three pillars – THINK, XCHANGE, ACT – and invest in the innovations that make a difference to lives globally.

www.fii-institute.org

About Interstellar Lab

Interstellar Lab is developing and building closed-loop sustainable living systems on Earth and in space. The company focuses on creating space-grade food production systems and habitat modules. The aim is double: to provide solutions regarding the current climate crisis and the need of new food production systems on Earth, and to develop closed-loop life support systems for lunar missions in the context of NASA’s Artemis Program and in the future for Mars exploration.

http://interstellarlab.earth

*Source : AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release

Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye